A personalized mRNA vaccine cuts melanoma recurrence by 44%
Published · Researched 2026-09-22
What happened (dated facts)
In Phase 2b results, the personalized mRNA cancer vaccine mRNA-4157 (V940), given in combination with pembrolizumab (Keytruda), reduced the risk of melanoma recurrence or death by 44% compared with pembrolizumab alone in patients with high-risk resected melanoma. At 18 months, recurrence-free survival was 78.6% with the combination versus 62.2% with pembrolizumab alone. The vaccine is custom-built for each patient from the mutations in their own tumor — up to 34 neoantigens per dose. The therapy remains investigational; a larger Phase 3 program is underway.
Why it is genuinely positive
A vaccine built from a patient's own tumor mutations, added to standard immunotherapy, kept significantly more melanoma patients cancer-free. It is one of the strongest clinical signals yet that personalized mRNA cancer vaccines can work in humans — and it is already in Phase 3 testing.
Social pulse
Strong oncology-press circulation of the Phase 2b results. On Threads, targeted searches returned posts about Russia's unrelated personalized mRNA program — no direct posts about Moderna/Merck's V940 were captured. The social layer here is oncology media rather than viral patient posts.
Verified quotes
None captured.
Verification
- Tier: 2
- Primary source: Clinical Trials Arena analyst comment on the Phase 2b results (https://www.clinicaltrialsarena.com/analyst-comment/mrna-vaccine-moderna-melanoma/). Proves: 44% reduction in recurrence/death risk; 18-month RFS 78.6% vs 62.2%.
- Social sources: health-press layer + targeted Threads searches (direct story posts not captured — noted honestly). Proves: sustained coverage and community relevance via health media.
- Positivity check: randomized Phase 2b efficacy signal with a large effect size — genuine, with investigational status stated clearly.
Key facts
| Fact | Value | Source | Date |
|---|---|---|---|
| Regimen | Personalized mRNA-4157 (V940) + pembrolizumab vs pembrolizumab alone | Clinical Trials Arena | — |
| Risk reduction | 44% lower risk of recurrence or death | Phase 2b via Clinical Trials Arena | — |
| 18-month recurrence-free survival | 78.6% (combo) vs 62.2% (pembro alone) | Phase 2b via Clinical Trials Arena | — |
| Status | Investigational; Phase 3 underway | Clinical Trials Arena | 2026-09-22 |
UNVERIFIED points
- Social-layer posts about mRNA-4157/V940 were not yet observed; tier cannot be finalized until they are.
Sources
- Primary source: Clinical Trials Arena analyst comment on the Phase 2b results ( — retrieval date not recorded